Monogram Technologies Inc. ( NASDAQ: MGRM) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Larry Holub - Investor Relations Benjamin Sexson - Chief Executive Officer Noel Knape - Chief ...
Dr. Douglas Unis, Monogram’s Chief Medical (TASE:BLWV) Officer, described the advancements as transformative for the autonomous system, aiming to deliver a competitive robotic solution in the ...
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA’s Additional Information Request (AIR) ...
Hosted on MSN15d
MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00.MGRM READ THE FULL MGRM RESEARCH REPORT Regulatory Update On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company's ...
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR)Investigator Meeting and Clinical Trial Training Held at the Shalb ...
At the ribbon cutting are: Parker Roop (from left) and Joe Aguilar with Patrick Building Supply; Antwain Mitchell, Andrew Payne, Eli Wood, Paul Pascale, and Instructor Philip Steagall with Patrick ...
"The Investigator Meeting was a successful milestone in the preparation for Monogram's clinical trial," said Dr. Ajaykumar Yadav, Associate Vice President and Group Head of Clinical Research at ...
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Investigator Meeting and Clinical Trial Training Held at the ...
It’s gotten to the point where Roger’s personas have gone off to have stories of their own, and a full lore that keeps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback